Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer

Cancer

Volumn 115, Issue 4, 2009, Pages 800-811

  Bellone, Stefania ^a   Anfossi, Simone ^b   O'Brien, Timothy J ^c   Cannon, Martin J ^c   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^b   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CTL; dendritic cells; ovarian serous carcinoma; peptides; TADG 12

Indexed keywords

ALANYLGLUTAMINYLLEUCYLGLYCYLPHENYLALANYLPROLYLSERYLTYROSYLVALINE; GAMMA INTERFERON; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE; GLYCYLLEUCYLASPARTYLASPARTYLLEUCYLLYSYLISOLEUCYLSERYLPROLYLVALINE; HLA A2 ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; INTERLEUKIN 4; LEUCYLLEUCYLPROLYLASPARTYLASPARTYLLYSYLVALYLTHREONYLALANYLLEUCINE; LEUCYLLEUCYLPROLYLLEUCYLLYSYLPHENYLALANYLPHENYLALANYLPROLYLISOLEUCINE; LYSYLLEUCYLVALYLGLYCYLALANYLTHREONYLSERYLPHENYLALANYLGLYCYLISOLEUCINE; OKT 3; SERINE PROTEINASE; SERYLLEUCYLLEUCYLPROLYLLEUCYLLYSYLPHENYLALANYLPHENYLALANYLPROLYL ISOLEUCINE; SERYLLEUCYLLEUCYLSERYLGLUTAMINYLTRYPTOPHYLPROLYLTRYPTOPHYLGLUTAMINYL ALANINE; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE 12 PROTEIN; TYROSYLLEUCYLPROLYLLYSYLSERYLTRYPTOPHYLTHREONYLISOLEUCYLGLUTAMINYLVALINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ANTIBODY PRODUCING CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CANCER CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL KILLING; CELL SPECIFICITY; CELL STRAIN K 562; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DONOR; DOWN REGULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; INTRACELLULAR SPACE; LEUKOCYTE; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE FUNCTION; MOLECULAR RECOGNITION; NATURAL KILLER CELL; OVARY CANCER; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TARGET CELL;

AGED; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PEPTIDE FRAGMENTS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 60849121727     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24048     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin. 2007; 57:43-66.
2. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. Invasive Cervical Cancer. 5th ed. St Louis, MO: Mosby; 1997:51-106.
3. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. J Biol Chem. 2001; 276: 857-860.
4. Bignotti E, Tassi RA, Calza S, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 2006; 103:405-416.
5. Underwood LJ, Shigemasa K, Tanimoto H, et al. Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta. 2000; 1502: 337-350.
6. Sawasaki T, Shigemasa K, Gu L, Beard JB, O'Brien TJ. The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer. Tumour Biol. 2004; 25: 141-148.
7. Wallrapp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overex- pressed in pancreatic cancer. Cancer Res. 2000; 60:2602-2606.
8. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from 3 major technologies. Cancer Res. 2003; 63:8614-8622.
9. Zeh HJ III, Leder GH, Lotze MT, et al. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol. 1994; 39:79-86.
10. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide- pulsed autologous dendritic cells. Obstet Gynecol. 2000; 96: 422-430.
11. Santin AD, Hermonat PL, Ravaggi A, et al. Expression of CD56 by human papillomavirus E7-specific CD8+ cyto- toxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA- A2-matched cervical tumor cells. Clin Cancer Res. 2001; 7(3 suppl):804s-810s.
12. Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002; 87:8-16.
13. Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother. 2006; 55:63-67.
14. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 1997; 186:1183-1187.
15. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245-252.
16. Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006; 25:377-413.
17. Ge Q, Rao VP, Cho BK, Eisen HN, Chen J. Dependence of lymphopenia-induced T cell proliferation on the abun-dance of peptide/MHC epitopes and strength of their interaction with T cell receptors. Proc Natl Acad Sci USA. 2001; 98:1728-1733.
18. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996; 183:1917-1921.
19. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 16:203-213.